NASDAQ:IOVA - Iovance Biotherapeutics Stock Price, Forecast & News

Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."

Iovance Biotherapeutics Inc (NASDAQ:IOVA) announced its quarterly earnings results on Monday, November, 4th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.39) by $0.01. View Iovance Biotherapeutics' Earnings History.

Iovance Biotherapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Iovance Biotherapeutics.

12 brokerages have issued 1-year price objectives for Iovance Biotherapeutics' shares. Their forecasts range from $27.00 to $38.00. On average, they expect Iovance Biotherapeutics' stock price to reach $31.73 in the next twelve months. This suggests a possible upside of 46.6% from the stock's current price. View Analyst Price Targets for Iovance Biotherapeutics.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iovance Biotherapeutics.

Media stories about IOVA stock have trended somewhat negative on Monday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Iovance Biotherapeutics earned a coverage optimism score of -1.4 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Iovance Biotherapeutics.

Iovance Biotherapeutics saw a drop in short interest in the month of January. As of January 15th, there was short interest totalling 14,830,000 shares, a drop of 9.5% from the December 31st total of 16,390,000 shares. Based on an average daily volume of 1,270,000 shares, the short-interest ratio is currently 11.7 days. Currently, 12.8% of the company's stock are short sold. View Iovance Biotherapeutics' Current Options Chain.

Some companies that are related to Iovance Biotherapeutics include Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Qiagen (QGEN), BioNTech (BNTX), Moderna (MRNA), argenx (ARGX), Repligen (RGEN), bluebird bio (BLUE), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Crispr Therapeutics (CRSP), Allogene Therapeutics (ALLO) and Acceleron Pharma (XLRN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Portola Pharmaceuticals (PTLA), Applied Materials (AMAT), Immunomedics (IMMU), Kadmon (KDMN), BlackRock (BLK), CA (CA), Seattle Genetics (SGEN), Bristol-Myers Squibb (BMY), Novavax (NVAX) and Heron Therapeutics (HRTX).

Iovance Biotherapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Peregrine Capital Management LLC (0.43%), Rhenman & Partners Asset Management AB (0.38%), California Public Employees Retirement System (0.25%), Strs Ohio (0.10%), Tocqueville Asset Management L.P. (0.05%) and Dupont Capital Management Corp (0.02%). Company insiders that own Iovance Biotherapeutics stock include Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum. View Institutional Ownership Trends for Iovance Biotherapeutics.

IOVA stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Tocqueville Asset Management L.P., Rhenman & Partners Asset Management AB, Evanson Asset Management LLC and Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for Iovance Biotherapeutics.

IOVA stock was acquired by a variety of institutional investors in the last quarter, including Dupont Capital Management Corp, Virginia Retirement Systems ET AL, California Public Employees Retirement System, Intellectus Partners LLC and Strs Ohio. Company insiders that have bought Iovance Biotherapeutics stock in the last two years include Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum. View Insider Buying and Selling for Iovance Biotherapeutics.

Shares of IOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IOVA stock can currently be purchased for approximately $21.64.

Iovance Biotherapeutics has a market capitalization of $2.73 billion. The biotechnology company earns $-123,580,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis. Iovance Biotherapeutics employs 88 workers across the globe.View Additional Information About Iovance Biotherapeutics.

The official website for Iovance Biotherapeutics is http://www.iovance.com/.

Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The biotechnology company can be reached via phone at 650-260-7120 or via email at [email protected]